Net income fell by $197 million. That is the oddest number in Becton, Dickinson and Company's latest report, because revenue grew by $300 million in the three months ended June 30.
Sales rose 5.4% to $5.0 billion from $4.7 billion a year earlier. Operating income went the other way, falling 10.3% to $663 million, while the operating margin slipped from 15.6% to 13.3%. BDX sold more and kept less of each dollar.
The balance sheet does not show a business simply piling up unsold goods or unpaid invoices. Inventory fell 16% to $3.3 billion, and accounts receivable fell 19.7% to $2.4 billion. Cash still declined 3.7% to $708 million, while research and development spending rose 12.2% to $258 million.
Connected Care supplied one of the cleaner examples of the tension. Revenue increased 4.9%, helped by orders already in backlog, lease mix, and higher infusion-set utilization after a prior-period fluid-supply disruption. Segment income fell to $395 million from $417 million, and its margin dropped to 32.3% from 35.8%.
BDX described the pressure this way:
"The Connected Care segment's operating income as a percentage of revenues in the third quarter of 2026 compared with the third quarter of 2025 reflected the following: Lower gross profit margin in the third quarter of 2026 compared with the third quarter of 2025 primarily reflected an unfavorable impact from lower sales volumes and higher labor costs, partially offset by favorable product mix and pricing."
BDX, 10-Q, Aug. 6, 2026
That is not a demand collapse across the company. It is a margin problem inside a growing business, with labor costs doing more damage than product mix and pricing could offset in Connected Care.
Medical Essentials shows the pressure was broader. Segment income edged up to $617 million from $612 million, but its margin fell from 38.2% to 36.8%. BDX attributed the lower gross margin primarily to tariffs, higher labor costs, and foreign-currency translation, partly offset by lower manufacturing costs from its continuous-improvement work.
The company also disclosed that BioPharma Systems' gross margin was higher, helped by lower manufacturing costs, though higher raw-material and labor costs related to inflation, tariffs, and pricing reduced the benefit. R&D spending rose as BDX increased investment in product development.
That leaves the stock context unusually plain. BDX closed at $170.59 on Aug. 5, and its trailing P/E is 29.3x based on the latest annual facts. The valuation is not the filing's main surprise. The question is whether revenue growth can keep arriving while tariffs, labor, currency, and development spending claim a larger share of it.
BDX's next quarterly report should provide the next comparable read on Connected Care's margin, Medical Essentials' cost pressure, and whether the company continues to describe tariffs and labor as operating headwinds. The unresolved tension is simple: BDX is growing revenue, but profit is shrinking.
Source: Becton, Dickinson and Company's 10-Q filed Aug. 6, 2026.